Joseph O. Johnson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Joseph O. Johnson has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Theresa A. Boyle
Moffitt Cancer Center 4 Department of Pathology Tampa, Florida
33 shared publications - Abigail E. Lantz
University of South Florida Morsani College of Medicine, Tampa, FL
32 shared publications - Allison Bahr
Department of Molecular Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida
32 shared publications - Dung-Tsa Chen
Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA
32 shared publications - Edna R. Gordián
Department of Molecular Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida
32 shared publications - Harold I. Saavedra
Department of Basic Sciences, Ponce Health Sciences University-Ponce Research Institute, Ponce, USA
32 shared publications
Latest Publications
- 5 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- p. OF1-OF20
KRAS-G12C Inhibition–Induced Enrichment of MHC-Ihigh Immune-Active Tumor Cells Directs Immune-Effector TME Development to Augment Therapeutic Efficacy
Inhibition of KRASG12C (G12Ci) has shown promising clinical activity in several cancers; however, emergence of resistance is a major limitation to long-term benefit. It remains unknown how G12Ci affects the tumor-immune microenvironment and its association with resistance. We investigated the immune-modulatory impact of the G12Ci sotorasib in KrasG12C/Trp53−/− lung and colon carcinoma models. Single-cell RNA sequencing of tumors in both models demonstrated sotorasib-induced loss of proliferative tumor cells and the enrichment of immune-active tumor cells with elevated NF-κB and IFN signaling and elevated MHC-I expression. These changes led to an increased proportion of effector T cells and MHC-IIhigh macrophages in the tumors and a reduced proportion of regulatory myeloid cells. Furthermore, sotorasib-resistant tumors exhibited a marked reduction of MHC-Ihigh immune-active tumor cells and immune cell type changes. Enrichment of immune-active tumor cells was associated directly with sotorasib-induced activation of NF-κB and STAT1, leading to heightened responsiveness to inflammatory cytokines and upregulation of MHC-I and chemokine expression. These findings indicate that modulation of immune-active tumor cell populations is a key mechanism associated with G12Ci therapeutic efficacy and the development of resistance. Watch first author Mohammed L. Ibrahim, B. Pharm, PhD, from California Northstate University College of Medicine describe this article: https://vimeo.com/showcase/12408339?video=1227805308.
- 5 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- p. OF1-OF20
KRAS-G12C Inhibition–Induced Enrichment of MHC-Ihigh Immune-Active Tumor Cells Directs Immune-Effector TME Development to Augment Therapeutic Efficacy
Inhibition of KRASG12C (G12Ci) has shown promising clinical activity in several cancers; however, emergence of resistance is a major limitation to long-term benefit. It remains unknown how G12Ci affects the tumor-immune microenvironment and its association with resistance. We investigated the immune-modulatory impact of the G12Ci sotorasib in KrasG12C/Trp53−/− lung and colon carcinoma models. Single-cell RNA sequencing of tumors in both models demonstrated sotorasib-induced loss of proliferative tumor cells and the enrichment of immune-active tumor cells with elevated NF-κB and IFN signaling and elevated MHC-I expression. These changes led to an increased proportion of effector T cells and MHC-IIhigh macrophages in the tumors and a reduced proportion of regulatory myeloid cells. Furthermore, sotorasib-resistant tumors exhibited a marked reduction of MHC-Ihigh immune-active tumor cells and immune cell type changes. Enrichment of immune-active tumor cells was associated directly with sotorasib-induced activation of NF-κB and STAT1, leading to heightened responsiveness to inflammatory cytokines and upregulation of MHC-I and chemokine expression. These findings indicate that modulation of immune-active tumor cell populations is a key mechanism associated with G12Ci therapeutic efficacy and the development of resistance. Watch first author Mohammed L. Ibrahim, B. Pharm, PhD, from California Northstate University College of Medicine describe this article: https://vimeo.com/showcase/12408339?video=1227805308.
- Open Access
Collagen remodeling promotes a GPCR-mediated mechanosensory immune checkpoint in ADGRG1+ CD8+ T cells and serves as a spatial biomarker of response to immunotherapy
Accessibility of immune cells to the tumor microenvironment (TME) in many solid tumors can be influenced by extracellular matrix (ECM) deposition, organization, and remodeling within tumor stroma. Specifically, lysyl hydroxylase-2 (LH2)-catalyzed lysine hydroxylation in type-I collagen telopeptides leads to formation of intermolecular collagen cross-links creating a stiffened and proteolytically resistant, stable ECM. Advanced head and neck squamous cell carcinomas (HNSCC) frequently exhibit desmoplasia with elevated LH2 expression, and Immune-checkpoint (ICI) therapy is effective in only <20% patients, suggesting that ECM remodeling mechanistically governs the composition and function of TME infiltrates. We show that elevated LH2 and collagen alignment promotes stromal accumulation of CD8⁺ T-cells, and poor response to ICI in HPV-HNSCCs. Integration of clinical biopsies, transcriptomic datasets, and an immunocompetent syngeneic mouse model revealed that aligned collagen spatially restricts adhesion G protein–coupled receptor positive (ADGRG1⁺) CD8⁺ T-cells to activate a non-canonical GPCR-mediated mechanosensory program that drives dysfunction and exhaustion. Statement of significance: Desmoplasia is common in solid tumors, and immune checkpoint inhibitors benefit only some patients. Current biomarkers like PD-L1 and TMB have limited value. Our findings reveal a previously unrecognized collagen-ADGRG1 mechanosensory immune checkpoint, offering a clinically tractable, spatially resolved biomarker to better stratify patients for immunotherapy.
Open AccessCollagen remodeling promotes a GPCR-mediated mechanosensory immune checkpoint in ADGRG1+ CD8+ T cells and serves as a spatial biomarker of response to immunotherapy
Accessibility of immune cells to the tumor microenvironment (TME) in many solid tumors can be influenced by extracellular matrix (ECM) deposition, organization, and remodeling within tumor stroma. Specifically, lysyl hydroxylase-2 (LH2)-catalyzed lysine hydroxylation in type-I collagen telopeptides leads to formation of intermolecular collagen cross-links creating a stiffened and proteolytically resistant, stable ECM. Advanced head and neck squamous cell carcinomas (HNSCC) frequently exhibit desmoplasia with elevated LH2 expression, and Immune-checkpoint (ICI) therapy is effective in only <20% patients, suggesting that ECM remodeling mechanistically governs the composition and function of TME infiltrates. We show that elevated LH2 and collagen alignment promotes stromal accumulation of CD8⁺ T-cells, and poor response to ICI in HPV-HNSCCs. Integration of clinical biopsies, transcriptomic datasets, and an immunocompetent syngeneic mouse model revealed that aligned collagen spatially restricts adhesion G protein–coupled receptor positive (ADGRG1⁺) CD8⁺ T-cells to activate a non-canonical GPCR-mediated mechanosensory program that drives dysfunction and exhaustion. Statement of significance: Desmoplasia is common in solid tumors, and immune checkpoint inhibitors benefit only some patients. Current biomarkers like PD-L1 and TMB have limited value. Our findings reveal a previously unrecognized collagen-ADGRG1 mechanosensory immune checkpoint, offering a clinically tractable, spatially resolved biomarker to better stratify patients for immunotherapy.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity
Supplementary Table 2 from Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity
Supplementary Table 2 from Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity
Supplementary Table 3 from Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity
Supplementary Table 3 from Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity
Supplementary Table 1 from Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity
Supplementary Table 1 from Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity
Oncolytic virus therapies induce the direct killing of tumor cells and activation of conventional dendritic cells (cDC); however, cDC activation has not been optimized with current therapies. We evaluated the adenoviral delivery of engineered membrane-stable CD40L (MEM40) and IFNβ to locally activate cDCs in mouse tumor models. Combined tumor MEM40 and IFNβ expression induced the highest cDC activation coupled with increased lymph node migration, increased systemic antitumor CD8+ T-cell responses, and regression of established tumors in a cDC1-dependent manner. MEM40 + IFNβ combined with checkpoint inhibitors led to effective control of distant tumors and lung metastases. An oncolytic adenovirus (MEM-288) expressing MEM40 + IFNβ in phase I clinical testing induced cancer cell loss concomitant with enhanced T-cell infiltration and increased systemic presence of tumor T-cell clonotypes in non–small cell lung cancer (NSCLC) patients. This approach to simultaneously target two major DC-activating pathways has the potential to significantly affect the solid tumor immunotherapy landscape.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity
Oncolytic virus therapies induce the direct killing of tumor cells and activation of conventional dendritic cells (cDC); however, cDC activation has not been optimized with current therapies. We evaluated the adenoviral delivery of engineered membrane-stable CD40L (MEM40) and IFNβ to locally activate cDCs in mouse tumor models. Combined tumor MEM40 and IFNβ expression induced the highest cDC activation coupled with increased lymph node migration, increased systemic antitumor CD8+ T-cell responses, and regression of established tumors in a cDC1-dependent manner. MEM40 + IFNβ combined with checkpoint inhibitors led to effective control of distant tumors and lung metastases. An oncolytic adenovirus (MEM-288) expressing MEM40 + IFNβ in phase I clinical testing induced cancer cell loss concomitant with enhanced T-cell infiltration and increased systemic presence of tumor T-cell clonotypes in non–small cell lung cancer (NSCLC) patients. This approach to simultaneously target two major DC-activating pathways has the potential to significantly affect the solid tumor immunotherapy landscape.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Elevated Methionine Flux Drives Pyroptosis Evasion in Persister Cancer Cells
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Elevated Methionine Flux Drives Pyroptosis Evasion in Persister Cancer Cells
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Elevated Methionine Flux Drives Pyroptosis Evasion in Persister Cancer Cells
Supplemental Materials Methods with additional references.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Elevated Methionine Flux Drives Pyroptosis Evasion in Persister Cancer Cells
Supplemental Materials Methods with additional references.